Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells

Cell and Bioscience

Volumn 4, Issue 1, 2014, Pages

  Peng, Shiwen ^a   Song, Liwen ^a,b,c,d   Knoff, Jayne ^a   Wang, Joshua W ^a   Chang, Yung Nien ^e   Hannaman, Drew ^f   Wu, T C ^a   Alvarez, Ronald D ^g   Roden, Richard B S ^a   Hung, Chien Fu ^a,h  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^d TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^e Papivax LLC   (United States)

^f Ichor Medical Systems Inc   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calreticulin; CD4 depletion; DNA vaccine; Human papillomavirus; Immunosuppression; Immunotherapy

Indexed keywords

EID: 84897424385     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-4-11     Document Type: Article

References (42)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
2. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head and neck pathology 2012, 6(Suppl 1):S16-S24. 3394159, 22782220.
3. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl 5):F12-F23.
4. Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012, 30(Suppl 5):F168-F174.
5. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012, 30(Suppl 5):F24-F33. 3700362, 23199964.
6. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, Young M, Melnick S, Miotti P, Burk R. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91:226-236. 10.1093/jnci/91.3.226, 10037100.
7. Pantanowitz L, Michelow P. Review of human immunodeficiency virus (HIV) and squamous lesions of the uterine cervix. Diagn Cytopathol 2011, 39:65-72. 10.1002/dc.21364, 21162096.
8. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annual review of immunology 2000, 18:927-974. 10.1146/annurev.immunol.18.1.927, 10837079.
9. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27:5450-5459. 10.1016/j.vaccine.2009.07.005, 2745985, 19622402.
10. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Human gene therapy 1999, 10:2727-2740. 10.1089/10430349950016474, 10584920.
11. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer research 2000, 60:1035-1042.
12. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer research 2001, 61:1080-1088.
13. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer research 2001, 61:3698-3703.
14. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. The Journal of clinical investigation 2001, 108:669-678. 10.1172/JCI200112346, 209378, 11544272.
15. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. Journal of virology 2004, 78:8468-8476. 10.1128/JVI.78.16.8468-8476.2004, 479075, 15280455.
16. Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, Viscidi R, Tsai YC, He L, Chen PJ, Boyd DA, Wu TC. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. Journal of virology 2004, 78:4638-4645. 10.1128/JVI.78.9.4638-4645.2004, 387705, 15078946.
17. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer immunology, immunotherapy: CII 2012, 61:63-70.
18. Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. Journal of lower genital tract disease 2010, 14:124-129. 10.1097/LGT.0b013e3181c6f01e, 20354421.
19. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. Journal of virology 2007, 81:11585-11592. 10.1128/JVI.01577-07, 2168774, 17715230.
20. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009, 101:782-792. 10.1093/jnci/djp106, 2689872, 19470949.
21. Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, Wu TC. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008, 26:351-360. 10.1016/j.vaccine.2007.11.019, 2258233, 18096279.
22. Spee P, Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. European journal of immunology 1997, 27:2441-2449. 10.1002/eji.1830270944, 9341791.
23. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996, 5:103-114. 10.1016/S1074-7613(00)80487-2, 8769474.
24. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313. 10.1016/S1074-7613(01)00111-X, 11290339.
25. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. International immunology 2000, 12:1539-1546. 10.1093/intimm/12.11.1539, 11058573.
26. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898. 10.1038/sj.onc.1204860, 11753671.
27. Gao Q, Singh L, Kumar A, Srinivasan S, Wazer DE, Band V. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. Journal of virology 2001, 75:4459-4466. 10.1128/JVI.75.9.4459-4466.2001, 114197, 11287601.
28. Dalal S, Gao Q, Androphy EJ, Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. Journal of virology 1996, 70:683-688. 189867, 8551603.
29. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396:84-88. 10.1038/23962, 9817205.
30. Evans CF, Davtyan H, Petrushina I, Hovakimyan A, Davtyan A, Hannaman D, Cribbs DH, Agadjanyan MG, Ghochikyan A. Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimer's & dementia: the journal of the Alzheimer's Association 2013, [Epub ahead of print].
31. Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, Vittorino R, Rosenberg TJ, Hannaman D, Vasan S. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 2011, 29:795-803. 10.1016/j.vaccine.2010.11.011, 21094270.
32. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 2010, 28:1056-1061. 10.1016/j.vaccine.2009.10.111, 19896452.
33. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 2006, 24:4490-4493. 10.1016/j.vaccine.2005.08.014, 16140436.
34. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert review of vaccines 2010, 9:503-517. 10.1586/erv.10.42, 20450325.
35. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Science translational medicine 2012, 4:155ra138.
36. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer research 1996, 56:21-26.
37. Wang JW, Jagu S, Kwak K, Wang C, Peng S, Kirnbauer R, Roden RB. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology 2014, 449:304-316.
38. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR, Kast WM. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22:520-527. 10.1016/j.vaccine.2003.07.003, 14670335.
39. Peng S, Monie A, Kang TH, Hung CF, Roden R, Wu TC. Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther 2010, 17:1453-1464. 10.1038/gt.2010.106, 2972366, 20668481.
40. Pseudovirus Production [http://home.ccr.cancer.gov/lco/production.asp], Pseudovirus Production.
41. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M, Slater LA, Roden RB, Wu TC. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Human gene therapy 2001, 12:235-252. 10.1089/10430340150218387, 11177561.
42. Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu TC. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 2003, 10:1311-1320. 10.1038/sj.gt.3301982, 12883527.